|
Synonyms: OPN 7486 | OPN-7486 | PLX-7486
Compound class:
Synthetic organic
Comment: PLX7486 is a small molecule CSF1R/TRK/Fms kinases inhibitor. It is orally available, potent and selective, with attractive pharmaceutical properties and is being investiagted for its anti-neoplastic action [1].
The chemical structure of PLX7486 has not yet been disclosed. We will show this as soon as it is openly available. |
| No information available. |
Summary of Clinical Use  |
| PLX7486 is being evaluated in Phase 1 clinical trial, as monotherapy and in combination with other anti-cancer therapeutics (gemcitabine and nab-paclitaxel) in patients with advanced solid tumours (e.g. pancreatic cancers, cancers with activating Trk (NTRK) mutations or NTRK gene fusion mutations, and tenosynovial giant cell tumours)- see NCT01804530. |
| Mechanism Of Action and Pharmacodynamic Effects |
| The rational for using Trk inhibitors in targeted cancer therapy (i.e. in cancers harbouring NTRK1, 2, and 3 gene rearrangements encoding novel oncogenic fusions) is reviewed in [2]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01804530 | Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors | Phase 1 Interventional | Plexxikon | ||
